Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
deals
24
×
national blog main
24
×
seattle blog main
seattle top stories
24
×
life sciences
startups
new york blog main
raleigh-durham blog main
san diego blog main
san francisco blog main
san francisco top stories
boston blog main
detroit blog main
detroit top stories
national top stories
new york top stories
raleigh-durham top stories
san diego top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
indiana blog main
indiana top stories
national
biotech
cancer
fda
cancer immunotherapy
clinical trials
pfizer
merck
novartis
alzheimer's disease
eli lilly
gene therapy
investing
What
roundup
bio
drug
drugs
patients
cancer
companies
help
news
acquisitions
alzheimer’s
based
ceo
develop
developing
fda
gene
health
healthcare
life
medical
moves
nash
pfizer’s
pharmaceutical
sciences
seattle
software
startup
week
ahead
aims
amid
asco
biggest
billions
biogen’s
bombast
buy
cash
Language
unset
unknown
Current search:
" national blog main "
×
deals
×
" seattle top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Seattle’s TransformativeMed Carves Out Niche in Medical Specialties
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bardy Diagnostics to Ramp Up Cardiac Monitor Sales With $35M Raise
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Xealth Gets $11M, Aims to Be Surescripts of Digital Health Services
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Providence St. Joseph Acquires Seattle Blockchain Startup Lumedic
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Sentinel Healthcare Raises $2M For Hypertension-Monitoring Software
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More